Find A Research Study
Study Title: Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study
Category: Cancer, General
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Kas Badiozamani
Study Coordinator: Leila Ponce
Phone: 206-625-7373 Ext.67960
Email: Leila.Ponce@vmmc.org
What is the Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study study?
Treatment: Radiation (Chemotherapy may be given after RT at Physician's discretion. Planned resection is ok for patients with primary esophageal, lung, and rectal cancer.
Who can participate?
Inclusion and Exclusion Criteria:
- Patients with primary esophageal, lung, and rectal carcinoma who are to be treated with neo-adjuvant chemoradiotherapy before a planned resection.
- Patients with primary, local, or regional carcinoma of the head/neck, lung, esophagus, or cervix receiving definitive therapy.
- Patients with clinically localized prostate cancer being treated with definitive external beam radiotherapy; brachytherapy may be delivered AFTER external beam radiotherapy
- Prior and concurrent hormone therapy is allowed
- No prior chemo or RT w/in 6 months of enrollment
Study Summary:
The purpose of this study is to investigate specific proteins in the blood of and their response to ionizing radiation. This information will be used to aid in understanding and predicting individual responses to radiation therapy that may allow for more personalized dosing of radiation therapy, with the goal of reducing side effects and improving cure rates.
Detailed Study Description:
Treatment: Radiation (Chemotherapy may be given after RT at Physician's discretion. Planned resection is ok for patients with primary esophageal, lung, and rectal cancer.
Study Design: Observational
Phase of Study: n/a
Study Type: Observational
Condition or Study Focus: Esophageal, lung, rectal, head/neck, or cervical cancers
Intervention Type: Other
Intervention Name: N/A
Gender: Male and Female
Age group: Observational
Sponsor: Benaroya Research Institute, Fred Hutchinson Cancer Research Institute
Other studies in this category include:
Studies currently accepting study participants:
- A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- Brain Metastases in NSCLC (RTOG 0320)
- Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy
- Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study
- Liver Cancer (Hepatocellular Carcinoma): Sorafenib vs Placebo as Adjuvant Treatment
- Liver Cancer (Hepatocellular Carcinoma): TACE for Intermediate Stage
- Lymphoma (S0313)
- Maintenance therapy for advanced ovarian or peritoneal cancer (GOG 0212)
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524)
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- SWOG S0016
- Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Failed First-Line Sunitinib
- Trial of FOLFOX with or without cetuximab for colon cancer
Studies currently not accepting study participants:
- Colorectal: A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Kidney Cancer (Renal Cell Carcinoma): Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)
- Liver Cancer (Hepatocellular Carcinoma): Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable (Advanced or Metastatic) Liver Cancer
- Methylphenidate in Treating Patients With Fatigue Caused by Cancer
- MK0646 for Patients with Advanced Cancer
- Open Label Study of Human Corticotropin-Releasing Factor (hCRF)
- Phase I, oral agent for Advanced Cancers
- Randomized Study comparing Human Corticotropin-Releasing Factor to Placebo for Patients Requiring High-dose Dexamethasone
- Stage IV Urothelial Cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer
- Weekly Topotecan (HyCamtin®) with Bevacizumab (Avastin®) Ovarian, Fallopian tube and/or Peritoneal Cancer